Kindeva Drug Delivery, a Woodbury, Minnesota-based global leader in drug-device combination products, acquired Summit Biosciences Inc., a Lexington, KY-based intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders.
The amount of the deal was not disclosed.
Established in 2009 and led (so far) by departing Chairman and CEO Richard D. Cohen, Summit has an extensive track record of innovation in the unit dose nasal spray market.
Led by CEO Milton Boyer, Kindeva is a global contract development manufacturing organization (CDMO) focused on drug-device combination products. The company develops and manufactures products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Kindeva’s service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our nine manufacturing, research, and development facilities located in the U.S. and U.K.
The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding its ability to serve biopharma customers across a wider range of complex drug-device combination products (pulmonary, injectable, transdermal, and nasal). Summit’s 55,000-square-foot cGMP facility in Lexington (Kentucky) adds to Kindeva’s global manufacturing footprint of nine development and manufacturing facilities across the U.S. and U.K. The facility is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and features specialized laboratories and integrated manufacturing operations with a long track record in bringing intranasal medicines to market.
FinSMEs
18/01/2024